165 related articles for article (PubMed ID: 33896649)
61. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
62. Mediastinal lymphomas: primary mediastinal (thymic) large B-cell lymphoma versus classical Hodgkin lymphoma, histopathologic dilemma solved?
Pervez S; Khawaja RD
Pathol Res Pract; 2010 Jun; 206(6):365-7. PubMed ID: 20185248
[TBL] [Abstract][Full Text] [Related]
63. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas.
Kondratiev S; Duraisamy S; Unitt CL; Green MR; Pinkus GS; Shipp MA; Kutok JL; Drapkin RI; Rodig SJ
Am J Surg Pathol; 2011 Oct; 35(10):1531-9. PubMed ID: 21921781
[TBL] [Abstract][Full Text] [Related]
64. How I Diagnose Primary Mediastinal (Thymic) Large B-Cell Lymphoma.
Ondrejka SL; Ott G
Am J Clin Pathol; 2021 Sep; 156(4):497-512. PubMed ID: 34398178
[TBL] [Abstract][Full Text] [Related]
65. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
66. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.
Iwaki N; Sato Y; Kurokawa T; Maeda Y; Ohno K; Takeuchi M; Takata K; Orita Y; Nakao S; Yoshino T
Med Mol Morphol; 2013 Sep; 46(3):172-6. PubMed ID: 23512149
[TBL] [Abstract][Full Text] [Related]
67. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
68. Malignant hematopoietic cell lines: in vitro models for the study of primary mediastinal B-cell lymphomas.
Drexler HG; Ehrentraut S; Nagel S; Eberth S; MacLeod RA
Leuk Res; 2015 Jan; 39(1):18-29. PubMed ID: 25480038
[TBL] [Abstract][Full Text] [Related]
69. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
70. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
[TBL] [Abstract][Full Text] [Related]
71. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
72. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
73. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.
Veldman J; Visser L; Berg AVD; Diepstra A
Cancer Treat Rev; 2020 Jan; 82():101931. PubMed ID: 31756590
[TBL] [Abstract][Full Text] [Related]
74. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
Kluiver J; Poppema S; de Jong D; Blokzijl T; Harms G; Jacobs S; Kroesen BJ; van den Berg A
J Pathol; 2005 Oct; 207(2):243-9. PubMed ID: 16041695
[TBL] [Abstract][Full Text] [Related]
75. Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study.
Tao Y; Chen H; Liu D; Dai X
Leuk Res; 2021 Dec; 111():106669. PubMed ID: 34333276
[TBL] [Abstract][Full Text] [Related]
76. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
77. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma.
Leithäuser F; Bäuerle M; Huynh MQ; Möller P
Blood; 2001 Nov; 98(9):2762-70. PubMed ID: 11675349
[TBL] [Abstract][Full Text] [Related]
78. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
[TBL] [Abstract][Full Text] [Related]
79. PD-1 /PD-L1 checkpoint in hematological malignancies.
Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
[TBL] [Abstract][Full Text] [Related]
80. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.
Wen KW; Fakhri B; Menke J; Ruiz-Cordero R; Gill RM; Ohgami RS
Ann Diagn Pathol; 2020 Jun; 46():151534. PubMed ID: 32473554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]